Norwood, MA —May 2026— Hilltop Bio today announced the results of a randomized, blinded, placebo-controlled clinical safety study evaluating LPAT, an amnion-derived biologic therapy under development for feline applications. The study demonstrated a strong safety and tolerability profile across all treated subjects, supporting continued clinical development of the therapy.

LPAT is a novel regenerative biologic derived from amniotic tissue, containing naturally occurring cytokines, growth factors, extracellular matrix components, and exosomes that may support tissue repair and modulate inflammation. While amnion-based therapies have a long history of use in human medicine, controlled safety data in feline populations have remained limited—until now.

The study, conducted in 30 client-owned cats, evaluated the safety of a single administration of LPAT delivered either subcutaneously (SC) or intramuscularly (IM), compared to placebo. Cats were monitored over a 30-day period with follow-up assessments including physical examinations, vital signs, and adverse event reporting.

Key Findings:

• No treatment-emergent adverse events (TEAEs) were observed in any study group
• No injection-site reactions (pain, swelling, erythema, or discharge) were reported
• No systemic adverse events, including fever, lethargy, or gastrointestinal or respiratory abnormalities
• No clinically significant changes in vital signs across all subjects
• No serious adverse events (SAEs) or owner-reported concerns during the study period

“These findings represent an important milestone in advancing regenerative medicine for veterinary applications,” said Marc Bordelon, DVM, MBA, author of the study. “The absence of observable safety signals across both delivery routes reinforces LPAT’s potential as a well-tolerated therapeutic option in cats.”

The randomized and blinded study design strengthens confidence in the results, with consistent findings observed across all treatment groups, including placebo controls. Importantly, the route of administration—subcutaneous or intramuscular—did not appear to influence safety outcomes.

Although the study focused on short-term safety over 30 days, extended monitoring of all subjects is ongoing through 180 days post-administration to evaluate any delayed effects.

“These data provide a strong foundation for the next phase of development,” added Bordelon. “Our focus now is to build on this safety profile and explore LPAT’s therapeutic potential in targeted disease models.”

The results mark a significant step forward for Hilltop Bio’s pipeline of biologic therapies aimed at improving outcomes in companion animal health.

About Hilltop Bio

Hilltop Bio is a veterinary biotechnology company dedicated to developing innovative, biologic-based products for equine and canine patients. Leveraging the latest advances in regenerative science, Hilltop Bio’s mission is to deliver research-backed solutions that veterinarians and pet owners can trust.